



DPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/591,722
Applicants : Atsushi SAITOU et al.
Based on International
Appln. No. : PCT/JP2005/004189
International Filing Date : March 10, 2005
Title : AMINE-BASED COMPOUND AND USE
THEREOF

TC/A.U. : (Not Yet Assigned)
Examiner : (Not Yet Assigned)

Docket No. : MOEG-P100
Customer No. : 23290

**INFORMATION DISCLOSURE STATEMENT AND NOTIFICATION
OF COPENDING COMMONLY ASSIGNED RELATED APPLICATIONS**

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citations enumerated on the list of references cited (modified Form PTO-1449) appended hereto may be material to the patentability of the above-identified application and are therefore submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application by initialing the citations on the enclosed modified Form PTO-1449.

The following references were cited in the May 17, 2005 International Search Report, and a copy of the report is submitted herewith:

WO 2003/029218 A1 where US Publication No. 2004/254221 A1
is a member of the patent family.
WO 2002/094261 A1 where US Publication No. 2004/157818 A1
is a member of the patent family.
WO 2002/022600 A1 where US Publication No. 2004/171638 A1
(now US Patent No. 7,091,217) is a member of the patent family.

SAITOU et al. - Serial No. 10/591,722
Information Disclosure Statement and Notification Of
Copending, Commonly Assigned Related Applications
Attorney Docket: MOEG-P100

WO 2000/056729 A1 where US Patent 6,750,348 B1
is a member of the patent family.
WO 2004/024697 A1.

The International Search Report is relied upon as an English language statement of pertinency of the non-English language references. A copy of each reference should have been transmitted by the International Bureau, and so copies are not submitted herewith .

Pursuant to 37 CFR 1.98(a)(2), copies of the cited U.S. patents and U.S. patent publications are not required.

Copies of the following foreign references and the literature references listed on the attached Form PTO-1449 are enclosed:

Foreign References

EP 0 183 271 A2 relates to lysin derivatives having a proteinase inhibition activity.

EP 0 628 551 A1 relates to semicyclic urea derivatives as antihistaminic agents.

EP 0 646 598 A1 and JP 7-89988, and patent family member U.S. Patent No. 5,633,231 relate to valine-containing, substituted pseudopeptides and their preparation and use as anti-viral agents, in particular against cytomegaloviruses. English abstracts of the European and Japanese references are enclosed and are relied upon, along with U.S. Patent No. 5,633,231 as an English translation of the pertinent portions of the two foreign language references.

WO 98/006397 A1 relates to guanidine containing compounds and their use in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

WO 99/033787 A1 is commonly assigned and relates to amino acid derivatives and chemokine receptor antagonists containing the same as the active ingredient. An English abstract and the chemical formulas are relied upon as an English translation of the pertinent portions of the reference.

WO 00/006086 A2 relates to a method for treating rheumatoid arthritis or other forms of inflammatory arthritis by administering an agent to inhibit the activation of the CXCR4 receptor by SDF-1.

WO 01/010842 A2 relates to melanocortin-4 receptor binding compounds and treatment of MC4-R associated disorders, such as disorders associated with weight loss.

WO 01/079168 A1 is commonly assigned and relates to antiviral nitrogenous compounds. An English abstract and the chemical formulas are relied upon as an English translation of the pertinent portions of the reference.

Literature References

Molino, M. et al, Biochimica et Biophysica Acta (BBA), Molecular Basis of Disease, Vol. 1500, pp 227-240 (2000) relates to CXCR4 on human endothelial cells as both a mediator of biological responses and as a receptor for HIV-2.

Saishin Igaku, Vol. 53, No. 9, pp. 2031 (1998), relates to a mechanism of expressing drug-resistance of HIV-1 and a countermeasure thereto. The reference is discussed in the present specification [as Non-patent Document 1] at pages 1 and 3, and an English translation of the abstract is enclosed as a translation of the pertinent portions of the reference.

Nikkei Science, Oct., pp. 26-37 (1998) relates to improving HIV therapy. The reference is discussed in the present specification [as Non-patent Document 2] at pages 1 to 3, and an English version of the reference, Bartlett, John G. et al, "Improving HIV Therapy," Scientific American, pp 84-89 (July 1998) is also enclosed as a translation of the pertinent portions of the reference.

Molecular Medicine, Vol. 36, No. 9, pp. 1012-1017 (1999) relates to problems in anti-HIV therapy, especially where multiple drugs are used, including adherence to taking medicine and cost. The reference is discussed in the present specification [as Non-patent

Document 3] at pages 2 and 3, and an English translation of the abstract is enclosed as a translation of the pertinent portions of the reference.

Nikkei Science, Oct., pp. 42-49 (1998) relates to HIV vaccines. The reference is discussed in the present specification [as Non-patent Document 4] at pages 2 to 3, and an English version of the reference, Baltimore, David et al, "HIV Vaccines: Prospects and Challenges," Scientific American, pp 78-83 (July 1998) is also enclosed as a translation of the pertinent portions of the reference.

Six other references, each in the English language and each discussed in the present specification and pages 2 and 3 are: Science, 272, 872-877 (1996) [Non-patent Document 5]; Nature, 382, 829 -831 (1996) [Non-patent Document 6]; J. Exp. Med., 186, 1383 - 1387 (1997) [Non-patent Document 7]; J. Exp. Med., 186, 1389 - 1393 (1997) [Non-patent Document 8]; J. Exp. Med., 186, 1395 - 1400 (1997) [Non-patent Document 9]; and Nature, 410, 50-56 (2001) [Non-patent Document 10].

The pending U.S. applications discussed below and listed on the attached Form PTO-1449 are available on Private PAIR and accordingly copies of these applications are not required.

The Examiner is notified of the following copending commonly assigned related applications:

1. U.S. Serial No. 10/478,290, now U.S. Publication No. 2004/0157818 A1, filed 01/16/2004, inventors Mikiro YANAKA et al., entitled CRCX4-ANTAGONISTIC DRUGS COMPOSED OF NITROGEN-CONTAINING COMPOUND (FJIN-115).

2. U.S. Serial No. 10/487,718, now U.S. Publication No. 2004/0254221 A1, filed 03/31/2004, inventors Toru YAMAZAKI et al., entitled NOVEL NITROGENOUS COMPOUND AND USE THEREOF (FJIN-116).

SAITOU et al. - Serial No. 10/591,722
Information Disclosure Statement and Notification Of
Coping, Commonly Assigned Related Applications
Attorney Docket: MOEG-P100

3. U. S. Serial No. 10/516,158, now U.S. Publication No. 2005/0165063 A1
filed 09/05/2003, now U.S. Patent No. 7,176,227, inventors Toru YAMAZAKI et al.,
entitled AMINE COMPOUND AND USE THEREOF (FJIN-118).

4. U.S. Serial No. 11/704,860, now U.S. Publication No. 2007/0208033 A1,
filed 2/9/2007, inventors, Toru YAMAZAKI et al, entitled AMINE COMPOUND AND
USE THEREOF (FJIN-118CIP).


The copending applications are listed on the attached Form PTO-1449 as their
published application.

This Information Disclosure Statement Under 37 CFR 1.56 is not to be construed:
1) as an admission that the information cited is, or is considered to be material to
patentability as defined in 37 CFR 1.56(b), 2) as a representation that a search has been
made, 3) that additional information that may be material to the patentability of this
application does not exist, or 4) that any one or more of these citations constitute prior art
under 35 U.S.C. 102.

SAITOU et al. - Serial No. 10/591,722
Information Disclosure Statement and Notification Of
Copinging, Commonly Assigned Related Applications
Attorney Docket: MOEG-P100

If any fees are due upon filing of this document, please charge our Deposit
Account No. 501032 (MOEG-P100).

Respectfully submitted,




Barry I. Hollander
Reg. No. 28,566

Hollander Law Firm, P.L.C.
Suite 305, 10300 Eaton Place
Fairfax, Virginia 22030
(703) 383-4800

Date: September 25, 2007

Enclosures:

Form PTO-1449 (4 sheets)
Copy of 5/17/05 International Search Report
Copy of each foreign reference not cited
on the international search report
and each literature reference cited

<p align="center"><u>CERTIFICATE OF MAILING</u></p> <p>I hereby certify that this correspondence dated <u>9/25/07</u> is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on <u>9/25/07</u>.</p> <p align="center"> HOLLANDER LAW FIRM, P.L.C. Suite 305 10300 Eaton Place Fairfax, Virginia 22030 Date: <u>9/25/07</u></p>
--